Gyre Therapeutics GYRE
Valuation
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 10th percentile, 5-year average 62.6x
Around its usual level · 47th percentile, 5-year average 2.1x
#4222 of 5311 stocks by PB (1 = cheapest)
Around its usual level · 42nd percentile, 5-year average 5.2x
#3755 of 5150 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 4.47 | – | 2.11 | 47% (cheaper than usual) | #4222 of 5311 (1 = cheapest) |
| PE | -21.69 | -13.58 | 62.59 | 10% (cheaper than usual) | – |
| PS | 4.40 | 3.88 | 5.20 | 42% (cheaper than usual) | #3755 of 5150 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on GYRE.